Selenious Acid

Summary

Selenious Acid (CHEMBL2009089) is an approved small molecule; indicated across 1 condition including severe acute respiratory syndrome.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 3
• Chemistry: 128.99 Da · H2O3Se

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2009089
Name	Selenious Acid
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	1091
ChEBI	CHEBI:26642
Molecular formula	H2O3Se
Molecular weight	128.99
InChIKey	MCAHWIHFGHIESP-UHFFFAOYSA-N

SMILES: O[Se](=O)O

IUPAC name: selenous acid

Also known as: Monohydrated selenium dioxide, Selenious acid, Selenious acid component of multrys, Selenious acid component of tralement, Selenium (as selenious acid), Selenium dioxide, monohydrated, UN 3283, UN-3283, SID144207605, SELENIOUS ACID

Parent form; salt/anhydrous children: CHEMBL112302, CHEMBL2028294

Patent coverage: 7,522 distinct patent families (15,448 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 15,392 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
severe acute respiratory syndrome	2	MONDO:0005091	MONDO:0100096

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE4	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05661682	PHASE4	WITHDRAWN	Tralement Versus a Fixed-dose Trace Element Combination Product to Evaluate Manganese Safety
NCT05677126	PHASE4	WITHDRAWN	Tralement vs. Fixed-dose Trace Element Combination Product in Patients >3 to 17 Years of Age Requiring Long-term PN
NCT04869579	PHASE2	UNKNOWN	Selenium as a Potential Treatment for Moderately-ill, Severely-ill, and Critically-ill COVID-19 Patients.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).